Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future.

ABSTRACT: The PROteolysis TArgeting Chimeras (PROTACs) is an innovative technique for the selective degradation of target proteins via the ubiquitin-proteasome system. Compared with traditional protein inhibitor drugs, PROTACs exhibit advantages in the efficacy and selectivity of and in overcoming drug resistance in cancer therapy, providing new insights into the discovery of anti-cancer drugs. In the last two decades, many PROTAC molecules have been developed to induce the degradation of cancer-related targets, and they have been subjected to clinical trials. Here, we comprehensively review the historical milestones and latest updates in PROTAC technology. We focus on the structures and mechanisms of PROTACs and their application in targeting tumor-related targets. We have listed several representa

SUBMITTER: Li R 

PROVIDER: S-EPMC9785308 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature